Novavax Initiates Phase 2 Trial of RSV Vaccine; Sees Reporting Top-Line Results in Q1 2013
Novavax, Inc. (Nasdaq: NVAX) today announced that enrollment has begun in a Phase 2 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age. The study is being conducted in collaboration with PATH, an international nonprofit organization that transforms global health through innovation, which is providing approximately $2 million in funding to support the trial.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.